Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Phage display peptide probes for imaging early response to bevacizumab treatment.

Cao Q, Liu S, Niu G, Chen K, Yan Y, Liu Z, Chen X.

Amino Acids. 2011 Nov;41(5):1103-12. doi: 10.1007/s00726-010-0548-9. Epub 2010 Mar 16.

2.

Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.

Pohl M, Werner N, Munding J, Tannapfel A, Graeven U, Nickenig G, Schmiegel W, Reinacher-Schick A.

Z Gastroenterol. 2011 Oct;49(10):1398-406. doi: 10.1055/s-0031-1281752. Epub 2011 Sep 30. Review.

PMID:
21964893
3.

Use of bevacizumab in metastatic colorectal cancer: report from the Mexican opinion and analysis forum on colorectal cancer treatment with bevacizumab (September 2009).

Zinser-Sierra JW, Rodríguez-Ramírez S, Villalobos-Valencia R, Ramírez-Márquez M.

Drugs R D. 2011;11(2):101-11. doi: 10.2165/11590440-000000000-00000. Review.

5.

Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.

Hsu JY, Wakelee HA.

BioDrugs. 2009;23(5):289-304. doi: 10.2165/11317600-000000000-00000. Review.

PMID:
19754219
6.

Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer.

Krämer I, Lipp HP.

J Clin Pharm Ther. 2007 Feb;32(1):1-14. Review.

PMID:
17286784
7.

Integration of novel agents in the treatment of colorectal cancer.

Iqbal S, Lenz HJ.

Cancer Chemother Pharmacol. 2004 Sep;54 Suppl 1:S32-9. Review.

PMID:
15309512
8.

Markers to predict the efficacy of bevacizumab in the treatment of metastatic colorectal cancer.

Varol U, Yildiz I, Salman T, Karabulut B, Uslu R.

Tumori. 2014 Jul-Aug;100(4):370-6. doi: 10.1700/1636.17888. Review.

9.

Anti-angiogenic therapies for metastatic colorectal cancer.

Wagner AD, Arnold D, Grothey AA, Haerting J, Unverzagt S.

Cochrane Database Syst Rev. 2009 Jul 8;(3):CD005392. doi: 10.1002/14651858.CD005392.pub3. Review.

PMID:
19588372
10.

Bevacizumab in colorectal cancer: current and future directions.

Yeung Y, Tebbutt NC.

Expert Rev Anticancer Ther. 2012 Oct;12(10):1263-73. doi: 10.1586/era.12.104. Epub 2012 Oct 31. Review.

PMID:
23113577
11.

Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.

Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D.

Curr Med Chem. 2006;13(16):1845-57. Review.

PMID:
16842197
12.

Targeted therapy with bevacizumab (Avastin) for metastatic colorectal cancer.

Koukourakis GV, Sotiropoulou-Lontou A.

Clin Transl Oncol. 2011 Oct;13(10):710-4. doi: 10.1007/s12094-011-0720-z. Review.

PMID:
21975331
13.

Use of bevacizumab in the treatment of metastatic colorectal cancer.

Raouf S, Bridgewater J, Ellis R, Ferry D, Hill M, Wasan H.

Br J Hosp Med (Lond). 2012 Jan;73(1):25-30. Review. Erratum in: Br J Hosp Med (Lond). 2012 Mar;73(3):174.

PMID:
22241406
14.

[Use of antibodies for colorectal cancer chemotherapy].

Kanemitsu K, Kakeji Y.

Nihon Rinsho. 2014 Jan;72(1):114-9. Review. Japanese.

PMID:
24597358
15.

Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer.

Fernando NH, Hurwitz HI.

Semin Oncol. 2003 Jun;30(3 Suppl 6):39-50. Review.

PMID:
12802794
16.

Phage peptide display.

Newton J, Deutscher SL.

Handb Exp Pharmacol. 2008;(185 Pt 2):145-63. doi: 10.1007/978-3-540-77496-9_7. Review.

PMID:
18626602
17.

Spotlight on bevacizumab in advanced colorectal cancer, breast cancer, and non-small cell lung cancer.

Lyseng-Williamson KA, Robinson DM.

BioDrugs. 2006;20(3):193-5. Review.

PMID:
16724868
18.

Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.

Jain RK.

Semin Oncol. 2002 Dec;29(6 Suppl 16):3-9. Review.

PMID:
12516032
19.

Is there a benefit from addiction to anti-VEGF therapy in patients with colorectal cancer?

Saif MW.

Anticancer Res. 2013 Jun;33(6):2377-80. Review.

PMID:
23749885
20.

Phage display in molecular imaging and diagnosis of cancer.

Deutscher SL.

Chem Rev. 2010 May 12;110(5):3196-211. doi: 10.1021/cr900317f. Review. No abstract available.

Supplemental Content

Support Center